An observational study in Diabetes Mellitus, sponsored by LMC Diabetes & Endocrinology Ltd.. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-11.
Sponsored by LMC Diabetes & Endocrinology Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 493 studies in Diabetes Mellitus with a site in Canada — 39 open to participants now, 55 under way, 5 of them phase 3. Diabetes Mellitus · Canada.
Among the 493 studies in Diabetes Mellitus with a site in Canada, this one is the 36th largest by enrollment of the 92 observational ones that give a count, is one of 14 that started in 2024, is one of 92 observational ones, and was the 475th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →39 of the 493 studies in Diabetes Mellitus with a site in Canada are open now. Recruiting first, the newest first:
May Faraj, PDt, PhD · Sites in Canada
Ages 40–70 · Healthy volunteers
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Pfizer · Sites in Canada, United States, Brazil and 8 more countries
Ages 18+
University of New Brunswick · Sites in Canada
Ages 19+ · Women only · Healthy volunteers
Trillium Health Partners · Sites in Canada
Ages 14+ · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
493 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 55 · Phase 3 126 · Phase 4 41
First in 1994; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is below the median of 246 across 1,935 observational studies indexed under Diabetes Mellitus.
Median enrollment 147 across the 397 interventional studies, 100 across the 92 observational. Of the 359 that completed or were terminated, 130 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 493 have an industry lead sponsor. The 10 most frequent:
LMC Diabetes & Endocrinology Ltd. is the lead sponsor of 22 studies on the registry; 4 are open to participants now.
LMC Diabetes & Endocrinology Ltd. has 9 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
15 of the studies in Diabetes Mellitus with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT05195944University Health Network, TorontoSemaglutide vs Sitagliptin | 2026-12 |
| NCT05543720University Health Network, TorontoEvaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study | 2026-12 |
| NCT06405880University of AlbertaPharmacist Case Finding and Intervention for Vascular Prevention Trial | 2026-12 |
| NCT06589466University of AlbertaPreoperative Optimization of Diabetic Patients | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 493 studies in Diabetes Mellitus with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this retrospective, observational study, is to better understand the real-world glycemic effectiveness of switching to real time continuous glucose monitoring (rtCGM) from intermittently scanned continuous glucose monitoring (isCGM) among adults with type 1 diabetes or type 2 diabetes in Canada.
The study population includes adults, who were active patients with type 1 diabetes or type 2 diabetes at LMC, who switched from intermittently scanned continuous glucose monitoring to real-time continuous glucose monitoring (rtCGM switch cohort) or initiated and maintained intermittently scanned continuous glucose monitoring use (isCGM cohort).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
adults with diabetes that switched from an isCGM to an rtCGM
Device: real-time continuous glucose monitor
adults with diabetes that remained on an isCGM
Individuals who switched from using isCGM to rtCGM
Change in HbA1c at 6-12-month follow-up compared to baseline
To evaluate change in HbA1c at 6-12-month follow-up compared to baseline after switching from an isCGM system to a rtCGM system in adults with type 1 diabetes
Time frame: from index date to 6- to-12-month follow-up
Change in HbA1c in the rtCGM switch cohort compared to a matched isCGM cohort
To compare 6-12 month change in HbA1c in the rtCGM switch cohort, who switched from isCGM to rtCGM, compared to a propensity score matched isCGM cohort, who maintained isCGM use, among a subgroup of patients with T1D and HbA1c ≥ 7.5%.
Time frame: from index date to 6- to-12-month follow-up
Change in percent time in target glucose range (TIR) at 6-12 months follow-up
To evaluate change in percent TIR at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: from index date to 6- to-12-month follow-up
Change in percent time below target glucose range (TBR)
To evaluate change in percent TBR at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: from index date to 6- to-12-month follow-up
Change in percent time above target glucose range (TAR)
To evaluate change in percent TAR at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: from index date to 6- to-12-month follow-up
Change in mean glucose
To evaluate change in mean glucose at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: from index date to 6- to-12-month follow-up
Change in standard deviation (SD) of mean glucose
To evaluate change in SD of mean glucose at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: from index date to 6- to-12-month follow-up
Change in coefficient of variation (CV) of mean glucose
To evaluate change in CV of mean glucose at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: from index date to 6- to-12-month follow-up
Change in weight
To evaluate change in weight at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: from index date to 6- to-12-month follow-up
Proportion of patients who achieve HbA1c ≤7.0%
To evaluate the proportion of patients who achieve HbA1c ≤7.0% at 6-12 months follow-up in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% at baseline and propensity score matched isCGM cohort with HbA1c ≥ 7.5% at baseline.
Time frame: evaluated at 6- to-12-month follow-up
Weekly incidence of self-reported hypoglycemia
To evaluate weekly incidence of self-reported hypoglycemia at 6-12 months in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: evaluated at 6- to-12-month follow-up
Proportion of patients with ≥ 1 self-reported hypoglycemic event
To evaluate proportion of patients with ≥ 1 self-reported hypoglycemic event at 6-12 months in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: evaluated at 6- to-12-month follow-up
Change in total daily dose (TDD) of insulin
To evaluate change in TDD of insulin at 6-12 months follow-up compared to baseline in the rtCGM switch cohort, and between the rtCGM switch cohort with HbA1c ≥ 7.5% and propensity score matched isCGM cohort with HbA1c ≥ 7.5%.
Time frame: from index date to 6- to-12-month follow-up
Proportion of patients using a Tandem® insulin pump in the rtCGM switch cohort
To evaluate proportion of patients using a Tandem® insulin pump in the rtCGM switch cohort during the study period from baseline to 6-12 months follow-up.
Time frame: from index date to 6- to-12-month follow-up
Plan to share: No — This is a real-world study using data retrieved from a national Diabetes Registry. IPD will not be shared.
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Aug 2024, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
LMC Diabetes & Endocrinology Ltd.